ReviewBiomolecules2026
From GWAS Signals to Molecular Mechanisms: Explainable AI for Causal Gene Prioritization and Biomolecular Target Interpretation.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Genome-wide association studies (GWAS) have identified thousands of loci associated with complex human diseases. However, the majority of the association signals reside in non-coding regions of the genome, and do not directly reveal the causal variant, effector gene, regulatory biomolecule, cell type, pathway, biomarker, or therapeutic target. Because many disease-associated variants act through non-coding regulatory mechanisms, post-GWAS interpretation increasingly depends on fine-mapping, expression quantitative trait loci, transcriptome-wide association studies, and functional evidence from single-cell multi-omics, network biology, and genetic target prioritization. Artificial intelligence can attempt to integrate these heterogeneous molecular evidence layers, but the resulting black-box prediction is insufficient when outputs cannot be biologically reproduced or experimentally tested. This review evaluates explainable artificial intelligence (XAI) as a framework for linking genetic association signals to molecular mechanisms and causal gene hypotheses. We argue that explainability is best treated as a biological requirement because useful models must expose evidence paths from significant disease-associated variants to regulatory elements, genes, transcripts, proteins, pathways, cell states, and therapeutic hypotheses. By emphasizing transparent evidence provenance, ancestry-aware interpretation, and functional validation, XAI can support the translation of GWAS signals into molecularly testable hypotheses for target prioritization and precision molecular medicine. The review focuses on the question of how to accomplish AI-accelerated functionalization of GWAS outputs across complex human diseases and traits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.